Adult Still’s Disease Improves With Tocilizumab, Le Mans General Hospital Study

January 4, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MedPageToday -- Treatment with the anti-interleukin (IL)-6 receptor antibody tocilizumab (Actemra) led to rapid amelioration of arthritis and systemic symptoms in a small group of patients with refractory adult Still's disease.

Twitter
LinkedIn
Facebook
Email
Print

Europe